Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Paraganglioma × 3-Iodobenzylguanidine × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 2 Pheochromocytoma 1 Paraganglioma 1 Neuroblastoma 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

gallium Ga 68 dotatate 2 lutetium Lu 177 dotatate 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Iodine-131 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed

24 enrolled 8 charts

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡